40728-74-3

Basic information

• Product Name: 2-(3,4,5-trimethoxyphenyl)-4H-3,1-benzoxazin-4-one
• Synonyms: 2-(3,4,5-Trimethoxyphenyl)-4H-3,1-benzoxazin-4-one; 4H-3,1-benzoxazin-4-one, 2-(3,4,5-trimethoxyphenyl)-
• CAS NO: 40728-74-3
• Molecular Formula: C₁₇H₁₅NO₅
• Molecular Weight: 313.3047
• Mol File: 40728-74-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 442.3°C at 760 mmHg
• Flash Point: 191.4°C
• Density: 1.27g/cm³
• Vapor Pressure: 5.06E-08mmHg at 25°C
• Refractive Index: 1.582
• CAS DataBase Reference: 2-(3,4,5-trimethoxyphenyl)-4H-3,1-benzoxazin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4,5-trimethoxyphenyl)-4H-3,1-benzoxazin-4-one(40728-74-3)
• EPA Substance Registry System: 2-(3,4,5-trimethoxyphenyl)-4H-3,1-benzoxazin-4-one(40728-74-3)

Safety Data

• Hazardous Substances Data: 40728-74-3(Hazardous Substances Data)

Usage

Chemical structure

A benzoxazinone derivative with a 3,4,5-trimethoxyphenyl group attached to the phenyl ring

Pharmacological properties

Anti-inflammatory, anti-fungal, and anti-tumor activities

Potential applications

Natural herbicide, treatment of neurological disorders (inhibits acetylcholinesterase enzyme)

Industries of interest

Pharmaceutical and agricultural.

Upstream product

• 118-41-2 Eudesmic acid 
• 4521-61-3 3,4,5-Trimethoxybenzoyl chloride 
• 91-56-5 indole-2,3-dione 
• 1431097-97-0 C₁₇H₁₆INO₅ 
• 118-92-3 anthranilic acid 

Downstream Products

• 75586-78-6 methyl 2-<(3,4,5-trimethoxyphenyl)amino>benzoate 
• 83409-21-6 3-[1-Benzyl-2-oxo-2-(4-p-tolyl-piperazin-1-yl)-ethyl]-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83409-20-5 3-[1-Benzyl-2-oxo-2-(4-phenyl-piperazin-1-yl)-ethyl]-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83409-19-2 3-[3-Methyl-1-(4-p-tolyl-piperazine-1-carbonyl)-butyl]-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83409-17-0 3-[2-Methyl-1-(4-p-tolyl-piperazine-1-carbonyl)-propyl]-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83409-15-8 3-[3-Methyl-1-(4-phenyl-piperazine-1-carbonyl)-butyl]-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83409-13-6 3-[2-Methyl-1-(4-phenyl-piperazine-1-carbonyl)-propyl]-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83409-23-8 3-(1-Benzyl-2-morpholin-4-yl-2-oxo-ethyl)-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83409-18-1 3-[1-Methyl-2-oxo-2-(4-p-tolyl-piperazin-1-yl)-ethyl]-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83409-24-9 3-(1-Benzyl-2-oxo-2-piperidin-1-yl-ethyl)-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83409-22-7 3-(1-Benzyl-2-oxo-2-pyrrolidin-1-yl-ethyl)-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83409-14-7 3-[1-Methyl-2-oxo-2-(4-phenyl-piperazin-1-yl)-ethyl]-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83409-16-9 3-[2-Oxo-2-(4-p-tolyl-piperazin-1-yl)-ethyl]-2-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one 
• 83408-99-5 N,N-Diethyl-2-[4-oxo-2-(3,4,5-trimethoxy-phenyl)-4H-quinazolin-3-yl]-3-phenyl-propionamide 

Relevant articles and documents

Quinazolinone-schiff's base hybrids as phosphodiesterase 4b inhibitors with dual activity against COPD and lung cancer

A series of thirty compounds of quinazolinone-Schiff's base hybrids were rationally designed, synthesized, and evaluated for their in vitro Phosphodiesterase 4B inhibition, anti-lung and anti-colon cancer activities. Compounds 9, 16, 23, 29, 30, 31, 32 an

Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance

P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a principal obstacle for successful cancer chemotherapy. A novel P-gp inhibitor with a quinazoline scaffold, 12k, was considered to be the most promising for in-depth study. 12k possessed high potency (EC50 = 57.9 ± 3.5 nM), low cytotoxicity, and long duration of activity in reversing doxorubicin (DOX) resistance in K562/A02 cells. 12k also boosted the potency of other MDR-related cytotoxic agents with different structures, increased accumulation of DOX, blocked P-gp-mediated Rh123 efflux, and suppressed P-gp ATPase activity in K562/A02 MDR cells. However, 12k did not have any effects on CYP3A4 activity or P-gp expression. In particular, 12k had a good half-life and oral bioavailability and displayed no influence on DOX metabolism to obviate the side effects closely related to increased plasma concentrations of cytotoxic agents in vivo.

Synthesis of 2-Aryl-4H-3,1-Benzoxazin-4-ones: A Class of α-Chymotrypsin Inhibitors

Twenty one derivatives of 2-aryl-4H-3,1-benzoxazin-4-one were synthesized and their potential therapeutically significance and structureactivity relationship were tested against α-chymotrypsin. Majority of synthesized compounds showed significant in vitro α-chymotrypsin inhibitory properties having IC50values in the range of 5.42 ± 1.66 - 41.27 ± 1.33 μM, whereas standard inhibitor chymostatin have IC50 value 7.13 ± 1.06 μM. In the present series compounds 2-(2-fluorophenyl)-4H-3,1-benzoxazin-4-one (3h), 2-(2-bromophenyl)-4H-3,1- benzoxazin-4-one (3n) and 2-(1-naphthyl)-4H-3, 1-benzoxazin-4-one (3t) with IC50values 7.22 ± 0.75, 6.99 ± 0.29 and 5.42 ± 1.66 μM, respectively were found to be most active members of series, even better than standard inhibitor a-chymostatin.